Lenalidomide Zentiva (Lenalidomide)

Lenalidomide exerts its effect by binding to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex. This binding changes the complex’s substrate preference, leading to ubiquitination and proteasomal degradation of the transcription factors Ikaros and Aiolos. The loss of these proteins results in anti‑angiogenic activity, modulation of cytokine release, enhanced immune‑mediated tumor cell killing, and direct inhibition of malignant cell proliferation.

The specific dose of lenalidomide is individualized by the treating physician based on the patient’s diagnosis, disease stage, renal and hepatic function, and concomitant therapies. The prescriber determines the appropriate strength, frequency, and duration of treatment in accordance with approved labeling and clinical guidelines. Patients should follow the exact dosing instructions provided by their healthcare professional.

Lenalidomide is classified as Pregnancy Category X because it has demonstrated teratogenic and embryotoxic effects in animal studies and is contraindicated in pregnant women. Women of childbearing potential must use effective contraception before, during, and after treatment. The drug is also not recommended for breastfeeding mothers, as it may be excreted in milk and could harm the infant.

To place an order, visit the product page on gnhindia.com, submit an enquiry specifying the required quantity of Lenalidomide Zentiva, and provide your institutional or trade credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies the buyer’s eligibility, and then replies with pricing, availability, shipping details—including any required cold‑chain handling—and the necessary import documentation.

The primary alternative to lenalidomide in the same therapeutic class is thalidomide, another immunomodulatory agent. Compared with thalidomide, lenalidomide generally shows higher potency, a more favorable safety profile regarding peripheral neuropathy, and a reduced risk of severe constipation. However, both drugs share risks such as thrombosis and teratogenicity, and the choice between them depends on the specific clinical scenario, prior therapy, and patient tolerance.

Lenalidomide Zentiva should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original blister pack or container, protect them from moisture, light, and excessive heat. Do not store in the bathroom or near a kitchen sink. Ensure that the product is kept out of reach of children and that any unused medication is disposed of according to local regulations.

Lenalidomide is taken orally, usually as a whole tablet with or without food, according to the prescriber’s instructions. The dose is typically given once daily on a schedule that may include treatment cycles (e.g., 21 days on treatment followed by a 7‑day rest period), but the exact regimen is determined by the treating physician based on the indication and patient factors. Swallow the tablet whole; do not crush or split unless directed.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis, and hepatotoxicity. Additionally, lenalidomide can cause severe cytopenias, leading to increased infection risk, and it is highly teratogenic, requiring strict contraception. Patients should be monitored regularly for signs of these complications, and any concerning symptoms should prompt immediate medical evaluation.

Lenalidide is contraindicated in pregnant women, women who are not using effective contraception, and individuals with known hypersensitivity to lenalidomide or any of its excipients. Patients with uncontrolled active infections, severe hepatic impairment, or those who have experienced serious thromboembolic events without adequate anticoagulation should also avoid the drug. The prescribing physician must assess each patient’s medical history and risk factors before initiating therapy.